Hypogonadotropic hypogonadism 2 with or without anosmia: genes and variants
Explore variant evidence for Hypogonadotropic hypogonadism 2 with or without anosmia across 1 analyzed protein (FGFR1). Linked ClinVar records include 55 pathogenic or likely pathogenic variants, 273 variants of uncertain significance and 47 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Hypogonadotropic hypogonadism 2 with or without anosmia
FGFR1: Fibroblast growth factor receptor 1
Its fibroblast-growth-factor signaling controls proliferation, differentiation, migration, and developmental patterning in many tissues. Germline pathogenic variants can cause hypogonadotropic hypogonadism or craniosynostosis syndromes, while fusions and other activating alterations drive selected cancers.
55 ClinVar pathogenic / likely pathogenic and 320 uncertain variants in FGFR1 have source records linked to Hypogonadotropic hypogonadism 2 with or without anosmia. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to Hypogonadotropic hypogonadism 2 with or without anosmia
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| FGFR1 G348R | 348 | Ig-like C2-type 3 | Pathogenic / likely pathogenic (★★) |
| FGFR1 R254Q | 254 | Extracellular | Pathogenic / likely pathogenic (★★) |
| FGFR1 G97S | 97 | Ig-like C2-type 1 | Pathogenic / likely pathogenic (★★) |
| FGFR1 R250W | 250 | Extracellular | Pathogenic / likely pathogenic (★★) |
| FGFR1 R250Q | 250 | Extracellular | Pathogenic / likely pathogenic (★★) |
| FGFR1 P252R | 252 | Extracellular | Pathogenic / likely pathogenic (★★) |
| FGFR1 R254W | 254 | Extracellular | Pathogenic / likely pathogenic (★★) |
| FGFR1 Y99C | 99 | Ig-like C2-type 1 | Pathogenic / likely pathogenic (★★) |
| FGFR1 R78C | 78 | Ig-like C2-type 1 | Pathogenic / likely pathogenic (★★) |
| FGFR1 D133H | 133 | Extracellular | Pathogenic / likely pathogenic (★★) |
| FGFR1 D224H | 224 | Ig-like C2-type 2 | Pathogenic / likely pathogenic (★★) |
| FGFR1 G237S | 237 | Ig-like C2-type 2 | Pathogenic / likely pathogenic (★★) |
| FGFR1 G270D | 270 | Ig-like C2-type 3 | Pathogenic / likely pathogenic (★★) |
| FGFR1 P283R | 283 | Ig-like C2-type 3 | Pathogenic / likely pathogenic (★★) |
| FGFR1 C381R | 381 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| FGFR1 G490R | 490 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| FGFR1 G610D | 610 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| FGFR1 I639T | 639 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| FGFR1 E670K | 670 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| FGFR1 G687R | 687 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| FGFR1 W737R | 737 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| FGFR1 P745S | 745 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| FGFR1 G301D | 301 | Ig-like C2-type 3 | Pathogenic / likely pathogenic (★★) |
| FGFR1 P741S | 741 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| FGFR1 G97R | 97 | Ig-like C2-type 1 | Pathogenic / likely pathogenic (★) |
| FGFR1 T340A | 340 | Ig-like C2-type 3 | Pathogenic / likely pathogenic (★) |
| FGFR1 N659D | 659 | Protein kinase | Pathogenic / likely pathogenic (★) |
| FGFR1 A671P | 671 | Protein kinase | Pathogenic / likely pathogenic (★) |
| FGFR1 M719T | 719 | Protein kinase | Pathogenic / likely pathogenic (★) |
| FGFR1 R744I | 744 | Protein kinase | Pathogenic / likely pathogenic (★) |
| FGFR1 N659S | 659 | Protein kinase | Pathogenic / likely pathogenic (★) |
| FGFR1 C101F | 101 | Ig-like C2-type 1 | Pathogenic / likely pathogenic (★) |
| FGFR1 C178G | 178 | Ig-like C2-type 2 | Pathogenic / likely pathogenic (★) |
| FGFR1 Y228D | 228 | Ig-like C2-type 2 | Pathogenic / likely pathogenic (★) |
| FGFR1 I239T | 239 | Ig-like C2-type 2 | Pathogenic / likely pathogenic (★) |
| FGFR1 G337R | 337 | Ig-like C2-type 3 | Pathogenic / likely pathogenic (★) |
| FGFR1 L342S | 342 | Ig-like C2-type 3 | Pathogenic / likely pathogenic (★) |
| FGFR1 V427E | 427 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| FGFR1 V429E | 429 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| FGFR1 E531G | 531 | Protein kinase | Pathogenic / likely pathogenic (★) |
| FGFR1 K618N | 618 | Protein kinase | Pathogenic / likely pathogenic (★) |
| FGFR1 P663R | 663 | Protein kinase | Pathogenic / likely pathogenic (★) |
| FGFR1 V683G | 683 | Protein kinase | Pathogenic / likely pathogenic (★) |
| FGFR1 R718C | 718 | Protein kinase | Pathogenic / likely pathogenic (★) |
| FGFR1 P722H | 722 | Protein kinase | Pathogenic / likely pathogenic (★) |
| FGFR1 A361P | 361 | Extracellular | Pathogenic / likely pathogenic (★) |
| FGFR1 G348E | 348 | Ig-like C2-type 3 | Pathogenic / likely pathogenic |
| FGFR1 N264H | 264 | Ig-like C2-type 3 | Pathogenic / likely pathogenic |
| FGFR1 A604D | 604 | Protein kinase | Pathogenic / likely pathogenic |
| FGFR1 A608D | 608 | Protein kinase | Pathogenic / likely pathogenic |
| FGFR1 T695I | 695 | Protein kinase | Pathogenic / likely pathogenic |
| FGFR1 T726I | 726 | Protein kinase | Pathogenic / likely pathogenic |
| FGFR1 Q764H | 764 | Protein kinase | Pathogenic / likely pathogenic |
| FGFR1 V71M | 71 | Ig-like C2-type 1 | Pathogenic / likely pathogenic |
| FGFR1 N296S | 296 | Ig-like C2-type 3 | Pathogenic / likely pathogenic |
Uncertain variants prioritized for review in Hypogonadotropic hypogonadism 2 with or without anosmia
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| FGFR1 G610S | 610 | Protein kinase | Conflicting reports (★) | +7: 2 other pathogenic changes within 3 positions; G610D at the same position is pathogenic; seen in 6.8e-07 of gnomAD DNA copies; REVEL 0.971 |
| FGFR1 A671V | 671 | Protein kinase | Conflicting reports (★) | +7: 2 other pathogenic changes within 3 positions; A671P at the same position is pathogenic; seen in 8.2e-06 of gnomAD DNA copies; REVEL 0.800 |
| FGFR1 C101W | 101 | Ig-like C2-type 1 | Uncertain (★★) | +7: 2 other pathogenic changes within 3 positions; C101F at the same position is pathogenic; seen in 7e-07 of gnomAD DNA copies; REVEL 0.833 |
Which prediction tools work for Hypogonadotropic hypogonadism 2 with or without anosmia
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- CATVariant: 99 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 98 out of 100
- PolyPhen-2: 97 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- REVEL: 97 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 96 out of 100
- SIFT: 96 out of 100
- MetaLR: 95 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CADD: 93 out of 100
- MutPred: 91 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SpliceAI: 78 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- Pangolin: 69 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- phyloP: 65 out of 100
Same protein, different disease
- Hartsfield-Bixler-Demyer syndrome also has ClinVar records linked to FGFR1 variants; they fall mostly in different places as the Hypogonadotropic hypogonadism 2 with or without anosmia variants (13 pathogenic / likely pathogenic).
- Osteoglophonic dysplasia also has ClinVar records linked to FGFR1 variants; they fall partly in the same places as the Hypogonadotropic hypogonadism 2 with or without anosmia variants (5 pathogenic / likely pathogenic).
- Encephalocraniocutaneous lipomatosis also has ClinVar records linked to FGFR1 variants; they fall partly in the same places as the Hypogonadotropic hypogonadism 2 with or without anosmia variants (3 pathogenic / likely pathogenic).
Diseases related to Hypogonadotropic hypogonadism 2 with or without anosmia
- Pfeiffer syndrome, also linked to FGFR1
- Colorectal cancer, also linked to FGFR1
- Non-small cell lung carcinoma, also linked to FGFR1
- Hartsfield-Bixler-Demyer syndrome, also linked to FGFR1
- Idiopathic pulmonary fibrosis, also linked to FGFR1
- Jackson-Weiss syndrome, also linked to FGFR1
- Encephalocraniocutaneous lipomatosis, also linked to FGFR1
- Osteoglophonic dysplasia, also linked to FGFR1
- Renal cell carcinoma, also linked to FGFR1
- Holoprosencephaly, also linked to FGFR1
- Cerebellar hypoplasia, also linked to FGFR1
- Craniosynostosis, also linked to FGFR1
Frequently asked questions
Which genes have records linked to Hypogonadotropic hypogonadism 2 with or without anosmia?
This view contains 1 analyzed proteins: FGFR1. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 55 pathogenic or likely pathogenic variants, 273 variants of uncertain significance and 47 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 3 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 422 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center